The ability of p66KO NSCs to resist apoptosis and differentiate without EGFR-ERK signalling highlights the potential of targeting p66Shc in conditions where growth factor signalling is disrupted, such as neurodegenerative diseases or brain injuries. The gene discussed is EGFR; the disease is brain injury.